Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Claire Mazumdar, Chief Executive Officer of Bicara Therapeutics Inc (NASDAQ:BCAX), sold 24,734 shares of common stock for approximately $466,936, according to a Form 4 filing with the Securities and Exchange Commission. The transaction comes as BCAX shares have surged 64% over the past six months, according to InvestingPro data, with the company maintaining a GOOD financial health score.
The sales occurred in two tranches. On October 13, 2025, Mazumdar sold 11,445 shares at a weighted average price of $18.9205, with prices ranging from $18.73 to $19.635. On October 15, 2025, she sold 13,289 shares at a weighted average price of $18.842, with prices ranging from $18.73 to $18.98. The current stock price of $18.81 suggests slight overvaluation according to InvestingPro’s Fair Value analysis.
On the same dates, Mazumdar also exercised options to acquire a total of 24,734 shares of Bicara Therapeutics common stock at a price of $3.7898, for a total value of $93,736. With analyst price targets ranging from $8 to $48, InvestingPro subscribers can access 10+ additional exclusive insights about BCAX’s financial outlook and market position.
In other recent news, Bicara Therapeutics Inc. has received a significant boost as the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to its cancer treatment, ficerafusp alfa. This designation applies to the drug when used in combination with pembrolizumab for the first-line treatment of certain head and neck cancer patients. The FDA’s decision marks a notable advancement for the company’s treatment strategy, which targets tumors expressing programmed death-ligand 1, while excluding HPV-positive cases. Following this development, H.C. Wainwright reiterated its Buy rating for Bicara, maintaining a price target of $40.00. Similarly, TD Cowen has also reiterated its Buy rating, referencing the recent $8 billion acquisition of Merus by Genmab as a positive indicator for companies in the EGFR bispecific antibodies space. Additionally, Jones Trading has initiated coverage on Bicara with a Buy rating and a price target of $22.00, noting the promising clinical data from the company’s bispecific antibody treatment. These analyst ratings reflect a growing confidence in Bicara’s potential within the competitive landscape of cancer therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.